Trials / Completed
CompletedNCT06082986
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
A Multicenter, Retrospective, Observational Study Using Real-world Data to Describe the Effectiveness, Treatment Pattern and Safety of Ustekinumab Among Bio-naive Patients With Crohn's Disease in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Xian-Janssen Pharmaceutical Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ustekinumab | No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice. |
Timeline
- Start date
- 2023-10-09
- Primary completion
- 2024-06-05
- Completion
- 2024-06-05
- First posted
- 2023-10-13
- Last updated
- 2025-06-26
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06082986. Inclusion in this directory is not an endorsement.